Experience of 5 years adjustable continence therapy (ProACT): the surgical learning curve and patient outcomes

• by Lisa M. de Zeeuw, Coen H. H. Christiaans, Sebastiaan Remmers, Bertil F. M. Blok, Alexander B. Stillebroer

• March 22, 2026

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.

• by Kathryn Wighton

• July 8, 2026

• 4 min

Medical Oddities: Natural Doesn't Always Mean Safe

From the gym to the kitchen to romance, these studies challenge everyday assumptions.

• by Teraya Smith

• July 15, 2026

• 4 min

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

• by Kathryn Wighton

• January 27, 2026

• 3 min